DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Mateo, J; Carreira, S; Sandhu, S; Miranda, S; Mossop, H; Perez-Lopez, R; Nava Rodrigues, D; Robinson, D; Omlin, A; Tunariu, N; Boysen, G; Porta, N; Flohr, P; Gillman, A; Figueiredo, I; Paulding, C; Seed, G; Jain, S; Ralph, C; Protheroe, A; Hussain, S; Jones, R; Elliott, Tony; McGovern, U; Bianchini, D; Goodall, J; Zafeiriou, Z; Williamson, C; Ferraldeschi, R; Riisnaes, R; Ebbs, B; Fowler, G; Roda, D; Yuan, W; Wu, Y; Cao, X; Brough, R; Pemberton, H; A'Hern, R; Swain, A; Kunju, L; Eeles, R; Attard, G; Lord, C; Ashworth, A; Rubin, M; Knudsen, K; Feng, F; Chinnaiyan, A; Hall, E; de Bono, J

Affiliation

Institute of Cancer Research, London

Issue Date

2015-10-29

Metadata

Show full item record

Abstract

Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition with olaparib.

Citation

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. 2015, 373 (18):1697-708 N Engl J Med

Journal

The New England Journal of Medicine

URI

http://hdl.handle.net/10541/592954

DOI

10.1056/NEJMoa1506859

PubMed ID

26510020

Type

Article

Language

ISSN

1533-4406

Collections

All Christie Publications